Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Hassel

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100BAnnette Paschen, Antje Sucker, Bettina Hill, et al.
Frontiers in Oncology|November 12, 2020
Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and EffectiveJakob Liermann, Julia K Winkler, Mustafa Syed, et al.
American Journal of Hematology|July 1, 2020
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progressionMarco Basset, Kamal Hummedah, Christoph Kimmich, et al.
Frontiers in Immunology|December 24, 2024
Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture systemChristina Völzke, Lisa Ehrhardt, Laura Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2018
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOGUwe Hillen, Ulrike Leiter, Sylvie Haase, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100BAnnette Paschen, Antje Sucker, Bettina Hill, et al.
Frontiers in Oncology|November 12, 2020
Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and EffectiveJakob Liermann, Julia K Winkler, Mustafa Syed, et al.
American Journal of Hematology|July 1, 2020
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progressionMarco Basset, Kamal Hummedah, Christoph Kimmich, et al.
Frontiers in Immunology|December 24, 2024
Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture systemChristina Völzke, Lisa Ehrhardt, Laura Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2018
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOGUwe Hillen, Ulrike Leiter, Sylvie Haase, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
Pageof 4